Closed Solicitation · DEPARTMENT OF VETERANS AFFAIRS

    6505--NOTICE OF INTENT - SOLE SOURCE FOR PLUVICTO

    DEPARTMENT OF VETERANS AFFAIRS
    Sol. 36C26125Q0797Special NoticeMATHER, CA
    Closed
    STATUS
    Closed
    closed Sep 19, 2025
    POSTED
    Sep 16, 2025
    Publication date
    NAICS CODE
    325412
    Primary industry classification
    PSC CODE
    6505
    Product & service classification

    AI Summary

    The Department of Veterans Affairs intends to award a sole source contract to Novartis Pharmaceuticals for the purchase of Pluvicto, a specialized radiopharmaceutical for treating prostate cancer. This notice is not a request for competitive proposals, but interested parties may submit evidence of their capability by September 17, 2025.

    Contract details

    Solicitation No.
    36C26125Q0797
    Notice Type
    Special Notice
    Posted Date
    September 16, 2025
    Response Deadline
    September 19, 2025
    NAICS Code
    325412AI guide
    PSC / Class Code
    6505
    Primary Contact
    VICTORIA TORRES
    City
    MATHER
    State
    CA
    ZIP Code
    95655
    AI Product/Service
    product

    Description

    Department of Veterans Affairs (VA), Regional Procurement Office West (RPOW), Network Contracting Office (NCO) 21, on behalf of Veterans Integrated Service Network (VISN) 21 intends to award a sole source, firm-fixed-price delivery order to Novartis Pharmaceuticals Corporation 59 Route 10, East Hanover, NJ 07936, for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing. The VA Northern California Health Care System, 10535 Hospital Way, Mather, CA 95655, has a requirement for the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan). Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) is a highly specialized radiopharmaceutical. Pluvicto is a radiologic therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pluvicto is an FDA approved drug. Pluvicto manufactured and is a trademark of Novartis Pharmaceuticals Corporation. This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. Interested parties may give written notice to victoria.torres@va.gov by 5:00pm PDT on 09/17/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement. This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government. Inquiries shall be emailed to victoria.torres@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.

    Key dates

    1. September 16, 2025Posted Date
    2. September 19, 2025Proposals / Responses Due

    AI search tags

    Frequently asked questions

    6505--NOTICE OF INTENT - SOLE SOURCE FOR PLUVICTO is a federal acquisition solicitation issued by DEPARTMENT OF VETERANS AFFAIRS. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.

    SamSearch Platform

    Stop searching. Start winning.

    AI-powered intelligence for the right opportunities, the right leads, and the right time.